Recurrent molecular characteristics of the colorectal cancer cell lines panel that confer sensitivity to specific BRAF inhibitors include, as expected, BRAF mutations conferring sensitivity to 4 of the 5 inhibitors (Table 6). Here, BRAF is linked to colorectal cancer.